Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on December 15, 2006
Japanese Journal of Clinical Oncology 2007 37(1):23-29; doi:10.1093/jjco/hyl124
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/1/23    most recent
hyl124v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lin, Y.-C.
Right arrow Articles by Liaw, C.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, Y.-C.
Right arrow Articles by Liaw, C.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer after Anthracycline: A Final Analysis

Yung-Chang Lin, Hsien-Kun Chang, Jen-Shi Chen, Hung-Ming Wang, Tsai-Shen Yang and Chaung-Chi Liaw

Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, LinKuo, College of Medicine, Chang Gung University, Taipei, Taiwan

For reprints and all correspondence: Yung-Chang Lin, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, LinKuo, College of Medicine, Chang Gung University, 199 Tung-Hwa North Road, Taipei, Taiwan, 105. E-mail: yclinof{at}adm.cgmh.org.tw

Received April 28, 2006; accepted September 18, 2006

OBJECTIVE: The purpose of the study is to compare two taxanes/cisplatin combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxicity.

METHODS: Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane, were enrolled. Fifty patients were treated with docetaxel 60 mg/m2 and cisplatin 50 mg/m2, and 51 patients were treated with paclitaxel 175 mg/m2 and cisplatin 50 mg/m2. Each cycle repeated every 3 weeks.

RESULTS: The overall response rate was 62.5 and 42.6% in the docetaxel and palcitaxel groups respectively (P = 0.06). Median time to disease progression was 9.8 and 6.5 months in docetaxel and paclitaxel groups respectively (P = 0.15). The median overall survival time was 22.7 months in the docetaxel arm and 22.4 months in the paclitaxel arm. Grade 3/4 arthralgia/myalgia, sensory neuropathy and anemia occurred more frequently in the paclitaxel arm, while more mucositis, fatigue and neutropenia occurred in the docetaxel arm.

CONCLUSION: Taxane/cisplatin combinations were active for advanced breast cancer, while there appeared to be evidence in favor of a docetaxel/cisplatin combination. The toxicity in favor of docetaxel/cisplatin warrants future first-line clinical trials.

Key Words: metastatic breast cancer • taxanes • platinum • hemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.